Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase

Ji Quan Wang, Mingzhang Gao, Kathy D. Miller, George W. Sledge, Qi Huang Zheng

Research output: Contribution to journalArticle

99 Scopus citations

Abstract

Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/μmol specific activity at end of bombardment (EOB).

Original languageEnglish (US)
Pages (from-to)4102-4106
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume16
Issue number15
DOIs
StatePublished - Aug 1 2006

Keywords

  • Cancer imaging
  • Carbon-11
  • Epidermal growth factor receptor tyrosine kinase (EGFR-TK)
  • Iressa
  • Positron emission tomography (PET)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Synthesis of [<sup>11</sup>C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase'. Together they form a unique fingerprint.

  • Cite this